Retatrutide: The Triple Agonist That Could Redefine Obesity Treatment
Retatrutide is Eli Lilly's experimental triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show unprecedented weight loss of up to 24%. Here's what the research reveals.